Collaborative Development. 18 4.3 Pre-Clinical Activities......................................... 18 4.4
Collaborative Development. The Parties will each diligently collaborate in the development of Development Candidates for the purpose of selecting Collaboration Products and use diligent efforts to develop and bring such Collaboration Products to the market as soon as reasonably practicable. In connection therewith, each Party shall use efforts not less than those efforts it makes with respect to its own pharmaceutical products of comparable commercial potential, stage of development and patent protection. The role of each Party in the research and development process will be proposed by the Project Team Leader and approved by the Drug Development Committee, with each Party providing advisory and supporting services with respect to each phase of the process in which such Party may be actively or primarily involved. No clinical trials involving any Collaboration Product shall be commenced by or on behalf of either Party without the prior approval of the Drug Development Committee; provided, GenVec may conduct any such studies with or for an Asian Partner. Each Party shall ensure that its Development tasks are carried out adhering to ethical and safety standards customary in the industry.
Collaborative Development. The Parties recognize that since the Products will be developed both in the Ono Territory and the Array Territory, regulatory and budget efficiencies can be achieved through the Parties’ coordination and worldwide use of preclinical and clinical data and in cooperatively conducting certain joint Clinical Studies. Accordingly, the Parties agree that it is their mutual interest to cooperatively conduct the Approved Clinical Studies to be agreed upon and set forth in Joint Development Plans as described in Section 4.4 below.
Collaborative Development. The Parties acknowledge that they do not currently envision collaborative generation of inventions under this Agreement that will constitute Joint Inventions. In the event the Parties undertake collaborative development of such inventions, the Parties will establish an IP Review Board to determine ownership as between the Parties. In the event any disputes regarding ownership of such inventions cannot be resolved by the IP Review Board, the Parties will follow the procedure specified in Section 13.2 below. [***], the Parties will define and mutually agree upon terms related to intellectual property rights related to that specific area of development.
Collaborative Development. Magainin will supply to this collaboration its Know How, scientific findings and other research showing the IL-9 mechanism and its role in modulating allergic and asthmatic response to antigen. Genentech and Magainin will conduct the Initial Research, including certain proof of concept relating to the IL-9 mechanism in respiratory/immune reaction to antigen, as determined by the Joint Project Team and provided in the Joint Development Plan. In addition to which, Genentech wishes to develop a human or humanized Antibody (using Genentech proprietary Know How or a transgenic mouse), as well as possibly generate a mouse Antibody that reacts with or affects IL-9 or IL-9 receptors. The Initial Research shall begin on the Effective Date and last until such time that the Joint Project Team selects the Compound for clinical development, including Phases I and II testing by Magainin. All such Initial Research shall be conducted by the Parties together or individually as assigned to tasks by the Joint Project Team, at the sole expense of the Party completing the work and at -------------------------------------------------------------------------------- **Certain portions of this exhibit have been omitted based upon a request for confidential treatment that has been filed with Commission. The omitted portions have been filed separately with the Commission. Magainin's expense for Phases I and II Clinical Studies. Once the data from those trials merits the commencement of a Phase III Clinical Study (per the determination by the Joint Project Team), Genentech shall at its expense (subject only to Section 8.6 herein), design the Phase III Clinical Study and take the Compound into Phase III, or a pivotal trial, through and including filing of the NDA/BLA. Genentech will be responsible for manufacturing Compounds hereunder. Magainin may have a role in manufacturing (or contract manufacturing) Small Molecule Compounds if so decided by the Joint Project Team and approved by the JSC. In accordance with the JSC approved budget for the Collaboration Program, Genentech will provide quarterly funding in advance for Magainin Collaboration Program expenses with preferred equity in tranches of that same Series A equity provided in the Stock Purchase Agreement, of even date herewith.
Collaborative Development. (a) Section 4.1 of the License Agreement is hereby deleted in its entirety and replaced with the following:
Collaborative Development. AOSOS is a robust and comprehensive system that, based on past experience, requires a great deal of user input into the development process. As such, the AOSOS Consortium requires full participation from all of its members to represent their individual organization's interests, as well as the AOSOS Consortium's interests as a whole. The AOSOS Consortium is a collaboration of equals and endeavors to spread the workload equally over its members, so as to not unfairly burden a select few members. However, its members are also committed to aiding each other to the extent practical and strive to foster an environment that is beneficial to all members, so xxxx member sees value in maintaining their membership in the AOSOS Consortium for the long run. - CONTINUOUSLY IMPROVING PRODUCT Consistent with the WIA guiding principle of "continuous improvement," the AOSOS Consortium's vision for AOSOS is that of a robust, flexible work in progress evolving to meet the changing needs of its users and enhance one-stop service delivery. The AOSOS Consortium will continually prioritize suggested enhancements and work with USDOL/ETA and the AJBSC to balance available resources. - CUSTOMER DRIVEN DESIGN Although AOSOS needs to be responsive to legislative mandates, Federal policy, and State Workforce Investment Boards, the AOSOS Consortium needs to be mindful and incorporate the needs of workforce development professionals and end customers (employers, job seekers, and service providers) in AOSOS. ROLES OF THE AOSOS CONSORTIUM DEFINING THE BUSINESS FUNCTIONALITY AND ESTABLISHING PRIORITIES FOR THE DEVELOPMENT AND ENHANCEMENT OF AOSOS This is a primary and core function of the AOSOS Consortium. In carrying out this responsibility, the AOSOS Consortium needs to identify, define and prioritize the business requirements for the AOSOS product. In addition, it needs to ensure that Federal requirements and State and Local interests are appropriately represented and balanced as part of the process. USDOL/ETA and the AJBSC recognize and support the AOSOS Consortium as the official authority charged with determining AOSOS functional requirements and development priorities. WORKING WITH USDOL/ETA AND THE AJBSC TO ASSIST IN DEVELOPING THE STRATEGIC DIRECTION FOR THE EVOLUTION OF THE AOSOS AS A PRODUCT SHARED BY MULTIPLE STATES The AOSOS Consortium will continually monitor and evaluate how things work today and how it wants them to work tomorrow, with special focus on the time after USDOL/E...
Collaborative Development. Intel and Synchronicity hereby agree to engage in the collaborative development described in the SOW. If Synchronicity fails to perform its obligations under this License Agreement, Synchronicity shall appoint as many Synchronicity application engineers as necessary to resolve Synchronicity's performance deficiencies. The application engineer(s) must be approved by Intel prior to entering Intel facilities and shall be subject to Intel's standard security procedures. If Intel is unable to obtain Synchronicity's commitment to the performance of the SOW to Intel's satisfaction after having worked with a Synchronicity application engineer in an effort to fulfill Synchronicity's performance obligations under this License Agreement, Intel may terminate this License Agreement and all of its obligations under this License Agreement.
Collaborative Development. NYCOMED acknowledges and understands that all development of the Licensed Products, for all indications within the Field in the United States and the Territory, shall be conducted in collaboration with PHARMACYCLICS, as provided in this Article 8, except where either Party proceeds independently with respect to an additional indication, where provided under Section 8.7. The role of each Party and the funding obligations of each Party with respect to such collaborative development shall be as set forth in this Article 8 and by the JDC. All collaborative development of the Licensed Product in the Field and in the United States and the Territory shall be conducted only under the direction of the Joint Development Committee. NYCOMED shall have the right to proceed independently with human clinical development of a Licensed Product only as provided in Sections 8.7 and 8.10.
Collaborative Development. The Parties acknowledge that all development of the Catarex Products, for all indications within the B&L Field shall be conducted in collaboration as provided in this Article 4. The role of each Party and the funding obligations of each Party with respect to such collaborative development shall be as set forth in this Article 4.
